Additionally, TVB‐2640, another FASN inhibitor, is currently being evaluated in clinical trials for several solid cancers, including NSCLC [202], HER2+ advanced‐stage breast carcinoma [225], and high‐grade astrocytoma [226]. Here, FASN is linked to breast carcinoma.